New re­port re-ig­nites fresh buzz that Bay­er is prep­ping an R&D over­haul and job cuts

Just a few months af­ter a Ger­man pub­li­ca­tion re­port­ed that Bay­er was prep­ping a top-to-bot­tom R&D re­view to see how much mon­ey — and jobs — could be squeezed out, the ru­mor mill has turned smok­ing hot again with a re­port from Reuters that seems to con­firm the scut­tle­butt.

Ger­many’s Wirtschaftswoche got it start­ed at the end of May that the cuts reach up to 1,000 in the re­or­ga­ni­za­tion. Now Reuters re­ports that job cuts and out­sourc­ing are on the ta­ble as the Ger­man drug com­pa­ny looks to raise more cash to in-li­cense new ther­a­pies for its pipeline.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER